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Introduction: Implantation of mesenchymal stem cells (MSCs) has recently been reported to repair tissue injuries
through anti-inflammatory and immunosuppressive effects. We established dedifferentiated fat (DFAT) cells that
show identical characteristics to MSCs.
Methods: We examined the effects of 106 of DFAT cells infused through renal artery or tail vein on monoclonal
antibody (mAb) 1-22-3-induced glomerulonephritis (as an immunological type of renal injury) and adriamycin-induced
nephropathy (as a non-immunological type of renal injury) in rats. The mAb 1-22-3-injected rats were also implanted
with 106 of DFAT cells transfected with TSG-6 siRNA through tail vein.
Results: Although DFAT cells transfused into blood circulation through the tail vein were trapped mainly in lungs
without reaching the kidneys, implantation of DFAT cells reduced proteinuria and improved glomerulosclerosis and
interstitial fibrosis. Implantation of DFAT cells through the tail vein significantly decreased expression of kidney injury
molecule-1, collagen IV and fibronectin mRNAs, whereas nephrin mRNA expression was increased. Implantation of
DFAT cells did not improve adriamycin-induced nephropathy, but significantly decreased the glomerular influx of
macrophages, common leukocytes and pan T cells. However, the glomerular influx of helper T cells, was increased.
Implantation of DFAT cells decreased expression of interleukin (IL)-6 and IL-12β mRNAs and increased expression of
TNF-stimulated gene (TSG)-6 mRNA in renal cortex from mAb 1-22-3-injected rats. The basal level of TSG-6 protein was
significantly higher in DFAT cells than in fibroblasts. Expression of TSG-6 mRNA in MCs cocultured with DFAT cells
was significantly higher than in mesangial cells or DFAT cells alone. Systematic implantation of DFAT cells with
TSG-6 siRNA through tail vein did not improve proteinuria, renal dysfunction and renal degeneration in the mAb
1-22-3-injected rats.
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Conclusion: Systematic implantation of DFAT cells effectively ameliorated mAb 1-22-3-induced glomerulonephritis
through immunosuppressive effects accompanied by the suppression of macrophage infiltration and expression of
IL-6, IL-10 and IL-12β, and increased production of serum and renal TSG-6 that improved the mAb 1-22-3-induced renal
degeneration by the immunosuppressive effects of TSG-6. Thus DFAT cells will be suitable cell source for the treatment
of immunological progressive renal diseases.Introduction
Despite the availability of long-term therapies, chronic
renal failure caused by immunoglobulin A (IgA) ne-
phropathy, diabetic nephropathy and glomerulosclerosis
cannot be cured through current treatments. End-stage
renal disease is an appropriate application for regenera-
tive medicine. Regarding regenerative medicines for
chronic renal failure, the implantation of cells, including
stem cells and progenitor cells, has been experimentally
applied in treatments for progressive renal diseases [1].
To date, however, there have been no clinical trials of
cell implantation for progressive renal diseases. This is
because the complexity of the kidney structure prevents
efficient regeneration in response to single-source cell
implantation. As a source of cells for use in regenerative
medicine, embryonic stem cells or inducible pluripotent
stem cells possess a nearly unlimited capacity for self-
renewal and have the potential to differentiate into virtu-
ally any cell type. Thus, mesenchymal stem cells (MSCs)
have arisen to become a candidate cell source in regen-
erative medicine for kidney diseases.
Recent studies have shown that adipose tissue can
provide an alternative source of MSCs [2]. Adipose tis-
sue contains nonadipocyte cells, known as the stromal-
vascular fraction, which can be isolated by centrifugation
of collagenase-digested adipose tissue, which is comprised
of multipotent fibroblast-like cells, known as adipose-
derived stromal cells (ASCs) [3].
We established an adipogenic progenitor cell line de-
rived from mature adipocytes and named these cells as
dedifferentiated fat (DFAT) cells [4]. Clonally-expanded
DFAT cells showed the ability to differentiate into mul-
tiple mesenchymal cell lineages, indicating that DFAT
cells represent a type of multipotent progenitor cell. The
accessibility and ease of culture of DFAT cells support
their potential application to cell-based therapies [5]. In
contrast to ASCs, which contain a variety of cell types,
DFAT cells originate from a fraction of highly homoge-
neous mature adipocytes. This property of DFAT cells
will likely lead to higher safety and efficacy for clinical
cell therapies.
To evaluate the efficiency of cell therapy for progressive
renal diseases, animal models of sustained renal failure
are required. Proteinuria was maintained at a higher level
and blood urea nitrogen (BUN) and serum creatininelevels were higher in rats with unilateral nephrectomy,
after the administration of Thy-1.1 monoclonal antibody
(mAb) 1-22-3. Morphologically, typical sclerotic changes
were observed in the mAb 1-22-3 injected rats. These
findings suggest that the renal lesions in the mAb 1-22-3
rats provide a suitable model for chronic progressive
glomerulonephritis [6].
Implantation of MSCs has recently been reported to
repair tissue injuries through their anti-inflammatory
and immunosuppressive effects [7]. Implantation of MSCs
has been reported to suppress fibrosis of infarcted heart
[8], bleomycin-induced lung fibrosis [9], liver fibrosis [10]
and interstitial fibrosis of kidney [11]. Moreover, MSCs
have been established to have immunosuppressive effects.
Systemic infusion of MSCs has been reported to suppress
graft rejection in animal models, which has led to a num-
ber of clinical trials [12,13]. Implantation of MSCs has
been developed in a clinical study in which MSCs were re-
ported to effectively inhibit graft-versus-host disease in
Phase II studies [14].
DFAT cells have the potential to differentiate into line-
ages of mesenchymal tissue and the cell surface antigen
profile of DFAT cells has been shown to be very similar
to that of bone marrow MSCs [5]. We previously exam-
ined the effects of implantation of DFAT cells on habu
snake venom-induced chronic renal dysfunction in mice
and found improvement of glomerulosclerosis [15]. Thus,
DFAT cells may provide a source of cell therapy for severe
progressive renal diseases. In the present study, to evaluate
the ability of DFAT cells to serve as a cell source for
progressive renal diseases, we examined the effects of
implantation of DFAT cells in mAb 1-22-3-induced
glomerulonephritis (as an immunological type of renal
injury) and adriamycin-induced nephropathy (as a non-
immunological type of renal injury) in a rat model.Methods
Ethical considerations
Our investigation conformed to the Guide for the
Care and Use of Laboratory Animals: Eighth Edition
Washington, DC: The National Academies Press, 2011.
The ethics committee of Nihon University School of
Medicine approved all research protocols involving the
use of living animals.
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A hybridoma producing mouse anti-rat Thy 1.1 mAb 1-
22-3 (IgG3) was prepared by immunization of BALB/c
mice with collagenase-treated fresh rat glomeruli. Ascitic
fluid containing mAb 1-22-3 was produced in BALB/c
mice primed with 2,6,10,14-tetramethylpentadecane
(Sigma Chemical, St. Louis, MO, USA) and injected in-
traperitoneally with the hybridoma. The obtained fluid
was subjected to 50% ammonium sulfate precipitation
and the obtained immunoglobulin-rich fraction was di-
alyzed against phosphate-buffered saline (PBS).
Preparation of the DFAT cells from adipose tissue
Approximately 1 g of subcutaneous adipose tissue from
male Wistar rats was treated with collagenase and centri-
fuged. Adipocytes were isolated from the top layer. More
than 99% of the isolated cells were mature lipid-filled adi-
pocytes. The mature adipocytes floating on top of the cul-
ture medium attached to the upper surface of the culture
flasks within a few days. Approximately 10% to 20% of the
adherent cells flattened out by day 3 and changed to a
spindle-shaped morphology by day 7. The cells subse-
quently entered a proliferative log-phase upon inversion
of the flasks and changing of the media, and reached con-
fluence by day 14. During this stage, the cells lose the lipid
droplets completely and exhibit the fibroblast-like morph-
ology of DFAT cells.
Distribution of DFAT cells
DFAT cells from Wistar rats were labeled with a
Qtracker® Cell Labeling Kit (Molecular probes, Life
Technology, Tokyo, Japan). A total 106 labeled DFAT
cells was injected through the renal arteries or tail vein
in Wistar rats. One week after the injection, kidney,
aorta, liver and lungs were removed and fixed in 3% for-
malin in PBS and embedded in paraffin. Sections were
observed under a fluorescence microscope. Images were
obtained with a digital imaging system.
Experimental protocols
Experiment 1: Effects of implantation of DFAT cells on
mAb 1-22-3-induced nephritis. In all male Wistar rats
weighing 250 g, the right kidney was nephrectomized.
Control rats were observed without any further injections.
Other rats were injected with 1.0 mL saline containing
0.5 mg mAb 1-22-3 through the tail vein at seven days
after nephrectomy. Thirty-five days after the nephrectomy,
1.0 mL saline (Saline) or 106 DFAT cells in 1.0 mL saline
were injected through the renal artery (DFAT ia) or
through the tail vein (DFAT iv). Sixty-three days after the
nephrectomy, all rats were killed and the left kidney was
removed (Figure 1).
Experiment 2: Effects of implantation of DFAT cells on
adriamycin-induced nephropathy. In all male Wistar ratsweighing 250 g, the right kidney was nephrectomized.
Control rats were observed without any further injec-
tions. Other rats were injected with 1.0 mL saline con-
taining 4 mg/kg body weight adriamycin (Wako Junyaku
Inc. Tokyo, Japan) through the tail vein at seven days
after nephrectomy without DFAT cells (Saline) or with
106 DFAT cells in 1.0 mL saline. Rats were injected
through the renal artery (DFAT ia) or through the tail vein
(DFAT iv). Thirty-five days after the nephrectomy, all rats
were killed and the left kidney was removed (Figure 1).
Experiment 3: DFAT cells (2 x 105 cells) from Wistar
rats were transfected with 20 nM rat TNF-stimulated gene
(TSG)-6-small interfering (si) RNA or 20 nM control siRNA
purchased from Santa Cruz Biotechnology, Santa Cruz, CA,
USA in siRNA Transfection Medium (Santa Cruz). To con-
firm sufficient inhibition of expression of TSG-6 protein,
we performed ELISA analysis for siRNA transfected DFAT
cells 24 hours after transfection. In male Wistar rats weigh-
ing 250 g, the right kidney was nephrectomized. Rats were
injected with 0.5 mg mAb 1-22-3 and 106 DFATcells trans-
fected with TSG-6 siRNA or control siRNA through the tail
vein. Fourteen days after the injections, all rats were killed
and the left kidney was removed (Figure 1). Urinary protein
excretion was determined with a Bio-Rad protein assay kit
(Bio-Rad, Hercules, CA, USA). Serum BUN and creatinine
were measured by SRL Inc. (Wako, Saitama, Japan).
Morphological and immunohistological analysis
The 3-mm paraffin sections of removed renal cortex were
stained with hematoxylin and eosin (H & E). Renal cortical
thickness was measured under high magnification (×400).
The glomerular injury score (GIS) was obtained using the
following formula: ((0 × n0) + (1 × n1) + (2 × n2) + (3 ×
n3) + (4 × n4))/50. To semi-quantify the tubulointerstitial
area, 20 areas of renal cortex were randomly selected. The
percentage of each area that showed sclerofibrotic change
was estimated and assigned a score of 0, normal; 1, in-
volvement of <10% of the area; 2, involvement of 10% to
30% of the area; 3, involvement of 30% to 50% of the
area; or 4, involvement of 50% of the area. The tubu-
lointerstitial injury score (TIS) was calculated as ((0 ×
n0) + (1 × n1) + (2 × n2) + (3 × n3) + (4 × n4))/20.
Deparaffinized 5-μm sections were briefly incubated
with 3% H2O2 and then with primary antibody for 60 mi-
nutes, rinsed with Tris-buffered saline containing 0.1%
Tween 20, and incubated with a secondary antibody for
30 minutes. The primary antibodies used for immunohis-
tochemical analysis were as follows: ED1 (IgG1) recogniz-
ing pan monocytes/macrophages was purchased from
Chemicon International Inc. (Temecula, CA, USA); OX1
recognizing CD45+ common leukocytes was purchased
from Santa Cruz Biotechnology (Dallas, TX, USA); Mouse
anti-rat monoclonal antibody OX19 (IgG1) recognizing
rat CD5 antigen was used to detect and deplete pan T cells
Figure 1 Experimental procedures. Experiment 1: Effects of implantation of DFAT cells on mAb 1-22-3-induced nephritis. In Wistar rats weighing
250 g, the right kidney was nephrectomized (Neflec). Rats were injected with 0.5 mg mAb 1-22-3 through the tail vein seven days after nephrectomy.
Thirty-five days after nephrectomy, 1.0 mL saline or 106 DFAT cells were injected through the renal artery or tail vein. Sixty-three days after
nephrectomy, all rats were killed and the left kidney was removed. Experiment 2: Effects of implantation of DFAT cells on adriamycin-induced
nephropathy. In all male Wistar rats, the right kidney was nephrectomized. Seven days after nephrectomy, rats were injected with 4 mg/kg
body weight adriamycin through the tail vein and 106 DFAT cells were injected through the renal artery or through the tail vein. Thirty-five
days after the nephrectomy all rats were killed and the left kidney was removed. Experiment 3: DFAT cells (2 x 105 cells) from Wistar rats were
transfected with 20 nM rat TSG-6 siRNA or 20 nM control siRNA in siRNA Transfection Medium. In male Wistar rats weighing 250 g, the right
kidney was nephrectomized. Rats were injected with 0.5 mg mAb 1-22-3 through the tail vein and 106 DFAT cells transfected with TSG-6 siRNA
or control siRNA were injected through the tail vein. Twenty-one days after the nephrectomy, all rats were killed and the left kidney was
removed. DFAT, dedifferentiated fat; mAb, monoclonal antibody; TSG, TNF-stimulated gene.
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used to detect and deplete CD4+ T cells [17]. OX-19 and
OX-38 were precipitated from ascites using the corre-
sponding hybridoma (European Collection of Animal Cells,
Porton Down, Salisbury, UK). Counterstaining was then
performed before examination under a light microscope.
Determination of mRNA expression
Total RNA was extracted from renal cortices and cul-
tured cells with TRIzol reagent (Life Technologies) ac-
cording to the manufacturer’s instructions. Total RNA
(1 μg) was reverse transcribed into cDNA with random 9-
mers with a Takara RNA PCR Kit (AMV) Ver. 3.0 (Takara
Bio, Ohtsu, Japan). Real-time quantitative PCR was per-
formed with diluted cDNA using a FastStart TaqMan
Probe Master (Roche Applied Science, Basel, Switzerland)
and an SYBR Select Master Mix (Life Technologies) in an
ABI 7500 sequence detector (Life Technologies) according
to the manufacturer’s instructions. All assay-on-demand
primers and probes (Kim-1, collagen IV, fibronectin,
nephrin, TSG-6, TNF-α, IL-6, IL-10, IL-12β and TGF-
β1) were purchased from Life Technologies. Real-time
PCR data were analyzed with standard curves and nor-
malized to 18S ribosomal RNA with its specific primer
sets (5’ and 3’ primers: 5’-CGGCTACCACATCCAAG
GAA-3’ and 5’-GCTGGAATTACCGCGGCT-3’) asdescribed previously [18]. Correlation coefficients for
the standard curves were all >0.90.
Enzyme-linked immunosorbent assay
Levels of TNF-stimulated gene-6 (TSG-6) in culture
medium were determined using ELISA kits (R&D Systems,
Minneapolis, MN, USA). Conditioned medium for 106
DFAT cells or 106 fibroblasts was collected for 24 hours
incubation. The supernatants of all specimens were de-
tected by a multidetection microplate reader using a
double-antibody sandwich ELISA kit according to the
manufacturer’s protocols. The concentrations of TSG-6
were normalized to the total protein content.
Coculture of DFAT and mesangial cells
Glomeruli were isolated from kidneys of four-week-old
male stroke prone spontaneous hypertensive (SHR-SP)
rats. Glomeruli were isolated with a graded-sieve tech-
nique as described previously [19]. Mesangial cells
(MCs) from SHR-SP were plated at 4,000 cells per cm2
in the bottom well of a six-well transwell coculture sys-
tem (Corning Incorporated, Corning, NY, USA). DFAT
cells from Wistar rats were plated separately at 1,000
cells per cm2 on the upper inserts of six-well transwell
coculture system and cultured in RPMI + 20% fetal bovine
serum (FBS) for seven days. Levels of TSG-6 in culture
Figure 3 Effects of implantation of DFAT cells on proteinuria and renal function in mAb 1-22-3-induced glomerulonephritis. Wistar rats were
nephrectomized and injected without mAb 1-22-3 (Control) or with 0.5 mg mAb 1-22-3 through the tail vein seven days after the nephrectomy.
Thirty-five days after the nephrectomy, saline (Saline) or 106 DFAT cells were injected through the renal artery (DFAT ia) or tail vein (DFAT iv).
Sixty-three days after the nephrectomy, the left kidney was removed. Urinary protein excretion (A), and serum levels of BUN (B) and creatinine
(Cre) (C) were measured. Data are the mean ± SEM (n = 6). *P <0.05 and **P <0.01 in the indicated columns. BUN, blood urea nitrogen; DFAT,
dedifferentiated fat; mAb, monoclonal antibody; SEM, standard error of the mean.
Figure 2 Distribution of implanted DFAT cells. DFAT cells from Wistar rats were labeled with Qtracker. A total of 106 labeled DFAT cells was
injected through the renal artery or tail vein in Wistar rats. One week after the injection, kidney, aorta, liver and lung were removed and fixed in
3% formalin. Renal cortex after injections of DFAT cells through renal artery (A, B) and through tail vein (C). Arrows indicate glomerulus. Lung
(D), liver (E) and aorta (F), seven days after injection of DFAT cells through the tail vein. Bar = 50 μm. DFAT, dedifferentiated fat.
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tracted from MCs from SHR-SP or DFAT cells (RNeasy
Mini Kit; Qiagen, Valencia, CA, USA) and assayed for
TSG-6 by real-time quantitative PCR.
Statistical analysis
The values are reported as the mean ± SE. Student’s t-
test was used for unpaired data. Two-way analysis of
variance (ANOVA) with the Bonferroni/Dunn procedure
as post-test was also used. P <0.05 was considered to be
statistically significant.
Results
Distribution of implanted DFAT cells
A total 106 Qtracker®-labeled DFAT cells was implanted
through the renal artery or tail vein in Wistar rats. Most
of the DFAT cells implanted through the renal artery were
trapped in the glomerulus seven days after injection
(Figure 2A, 2B). Seven days after injection, DFAT cells
implanted through the tail vein were not delivered toFigure 4 Effects of implantation of DFAT cells on degeneration of renal co
nephrectomized and injected without mAb 1-22-3 (Control) or with 0.5 mg
Thirty-five days after the nephrectomy, saline (Saline) or 106 DFAT cells wer
Sixty-three days after the nephrectomy, the left kidney was removed. A) Th
hematoxylin and eosin (H & E). Renal cortical thickness was measured un
C) Tubulointerstitial injury score (TIS). Data are the mean ± SEM (n = 6). *P
dedifferentiated fat; mAb, monoclonal antibody; SEM, standard error of ththe kidney (Figure 2C). They were trapped mainly in
the lung (Figure 2D), but not in the liver (Figure 2E) or
aorta (Figure 2F).
Effects of implantation of DFAT cells on mAb
1-22-3-induced glomerulonephritis
Injection of mAb 1-22-3 continuously increased protein-
uria in rats. Implantation of DFAT cells through the
renal artery and tail vein reduced the increases in pro-
teinuria (not statistically significant). Systematic implant-
ation of DFAT cells through the tail vein showed the
greatest reduction of proteinuria (Figure 3A). Injection
of mAb 1-22-3 significantly (P <0.01) increased serum
levels of BUN and creatinine. Implantation of DFAT cells
through the renal artery and tail vein significantly
(P <0.05) decreased the increased serum levels of BUN
and creatinine (Figure 3B, 3C).
Histologically, renal cortex showed sclerosis of the
glomerulus, interstitial fibrosis with mesangium prolifer-
ation and infiltration of inflammatory cells two monthsrtex in mAb 1-22-3-induced glomerulonephritis. Wistar rats were
mAb 1-22-3 through the tail vein seven days after the nephrectomy.
e injected through the renal artery (DFAT ia) or tail vein (DFAT iv).
e paraffin sections of the removed renal cortex were stained with
der high magnification (x400). B) Glomerular injury score (GIS).
<0.05 and **P <0.01 in the indicated columns. Bar = 50 μm. DFAT,
e mean.
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mAb 1-22-3 significantly (P <0.01) increased the GIS
and TIS. Implantation of DFAT cells through the renal
artery and tail vein resulted in a significant (P <0.01)
reduction in the increased GIS (Figure 4B) and TIS
(Figure 4C). It is notable that systemic implantation,
rather than direct implantation, improved glomerulo-
sclerosis and interstitial fibrosis.
Figure 5 shows the effects of implantation of DFAT
cells on mRNA expression of renal injury markers and
nephrin in renal cortex from mAb 1-22-3-injected rats.
mAb 1-22-3-injection significantly (P <0.05) increased
the abundance of kidney injury molecule (Kim)-1, colla-
gen IV and fibronectin mRNAs. Direct implantation sig-
nificantly (P <0.05) decreased the abundance of Kim-1
(Figure 5A) and collagen IV mRNAs (Figure 5B). Sys-
tematic implantation significantly (P <0.05) decreased
the abundance of Kim-1, collagen IV and fibronectin
mRNAs (Figure 5A-5C). mAb 1-22-3-injection signifi-
cantly (P <0.01) decreased the abundance of nephrin
mRNA, which was significantly (P <0.01) increased by
direct implantation (Figure 5D).Figure 5 Effects of implantation of DFAT cells on mRNA expression of rena
rats. Wistar rats were nephrectomized and injected without mAb 1-22-3 (C
after the nephrectomy. Thirty five days after the nephrectomy saline (Saline
tail vein (DFAT iv). Sixty-three days after the nephrectomy, the left kidney w
the expression of Kim-1 (A), collagen IV (B), fibronectin (C) and nephrin (D
the indicated columns. DFAT, dedifferentiated fat; Kim-1, kidney injury moleEffects of implantation of DFAT cells on
adriamycin-induced nephropathy
Injection of adriamycin continuously increased protein-
uria in rats (Figure 6A). Systematic implantation of
DFAT cells significantly (P <0.05) increased proteinuria
compared to control (Figure 6A). Injection of adriamycin
significantly (P <0.05) increased serum levels of BUN
and creatinine. Implantation of DFAT cells did not affect
serum levels of BUN and creatinine (Figure 6B, 6C).
Figure 7 shows the effects of the implantation of DFAT
cells on adriamycin-induced degeneration of renal cortex.
Injection of adriamycin induced glomerulosclerosis and
interstitial fibrosis with a significant (P <0.01) increase in
TIS (Figure 7C). Implantation of DFAT cells did not affect
adriamycin-induced glomerulosclerosis and interstitial
fibrosis (Figure 7A-7C).
Effects of implantation of DFAT cells on leukocyte
accumulation in glomeruli in mAb 1-22-3-injected rats
To explore the immunocytological mechanisms of the effects
of the implantation of DFAT cells, we evaluated leukocyte
influx into the glomeruli in mAb 1-22-3-injected rats.l injury markers and nephrin in renal cortex in mAb 1-22-3-injected
ontrol) or with 0.5 mg mAb 1-22-3 through the tail vein seven days
) or 106 DFAT cells were injected through the renal artery (DFAT ia) or
as removed. Real-time quantitative PCR was performed to determine
) mRNAs. Data are the mean ± SEM (n = 6). *P <0.05 and **P <0.01 in
cule; mAb, monoclonal antibody; SEM, standard error of the mean.
Figure 6 Effects of implantation of DFAT cells on proteinuria and renal function in adriamycin-induced nephropathy. Wistar rats were nephrectomized
and were injected without adriamycin (Control) or with 4 mg/kg body weight adriamycin through the tail vein without DFAT cells (Saline) or with 106
DFAT cells that were injected through the renal artery (DFAT ia) or tail vein (DFAT iv) in rats after the nephrectomy. Urinary protein excretion (A) and
serum levels of BUN (B) and creatinine (Cre) (C) were measured. Data are the mean ± SEM (n = 4). *P <0.05 and **P <0.01 in the indicated columns.
BUN, blood urea nitrogen; DFAT, dedifferentiated fat; SEM, standad error of the mean.
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cant (P <0.01) increases in glomerular influx of ED1+ cells
(pan monocytes/macrophages) (Figure 8A), OX1+ cells
(common leukocytes) (Figure 8B) and OX19+ cells (pan T
cells) (Figure 8C) in renal cortex from mAb 1-22-3-
injected rats. Implantation of DFATcells through the renal
artery and tail vein significantly (P <0.05) decreased
the glomerular influx of ED1+, OX1+ and OX19+ cells
(Figure 8A-8C). Implantation of DFAT cells significantly
(P <0.05) increased the glomerular influx of OX38+ cells
(helper T cells) (Figure 8D).
Effects of implantation of DFAT cells on expression of
cytokines in renal cortex in mAb 1-22-3-injected rats
mAb-1-22-3 injection increased the expression of IL-6,
IL-10, IL-12β and transforming growth factor-beta 1 (TGF-
β1) mRNAs in renal cortex from Wistar rats. Implantation
of DFATcells decreased the abundance of IL-10 mRNA (not
significant) and resulted in a significant (P <0.05) reduction
in the increased abundance of IL-6 and IL-12β mRNAs
(Figure 9A-9C). Implantation of DFAT cells did not affect
the abundance of TGF-β1 mRNA (Figure 9D).
Effects of implantation of DFAT cells on generation of TNF-
stimulated gene 6 in DFAT cells in mAb 1-22-3-injected rats
Implantation of DFAT cells through the tail vein sig-
nificantly (P <0.05) increased the abundance of TSG-6mRNA in renal cortex from mAb 1-22-3-injected rats
(Figure 10A). Implantation of DFAT cells through the
renal artery and tail vein significantly (P <0.05) increased
the abundance of TNF-α mRNA in renal cortex from
mAb 1-22-3-injected rats (Figure 10B). Figure 10C shows
the production of TSG-6 protein in cultured fibroblasts
and DFAT cells stimulated with TNF-α. Basal levels of
TSG-6 protein in conditioned medium were significantly
(P <0.05) higher in DFAT cells than in fibroblasts. TNF-α
significantly (P <0.05) increased the production of TSG-6
proteins in conditioned medium from fibroblasts and
DFAT cells (Figure 10C). Serum levels of TSG-6, which
were significantly (P <0.01) increased in rats at 24 hours
after implantation of DFATcells (Figure 10D), were almost
undetectable.
Production of TNF-stimulated gene 6 from mesangial cells
by transwell coculture of DFAT cells
To investigate whether separately placed DFAT cells can
increase TSG-6 in MCs, we employed a transwell co-
culture system. TSG-6 concentration in conditioned
medium from MCs incubated with DFAT cells was sig-
nificantly (P <0.01) higher than in medium from MCs
or DFAT cells alone (Figure 11B). The abundance of
TSG-6 mRNA in MCs incubated with DFAT cells was
significantly (P <0.01) higher than MCs or DFAT cells
alone (Figure 11C), indicating that the separately
Figure 7 Effects of implantation of DFAT cells on degeneration of renal cortex in adriamycin-induced nephropathy. Wistar rats were nephrectomized
and were injected without adriamycin (Control) or with 4 mg/kg BW adriamycin through the tail vein without DFAT cells (Saline) or with 106 DFAT cells
injected through the renal artery (DFAT ia) or tail vein (DFAT iv) after nephrectomy. A) The paraffin sections of removed renal cortex were
stained with hematoxylin and eosin (H & E). Renal cortical thickness was measured under high magnification (x400). B) Glomerular injury score
(GIS). C) Tubulointerstitial injury score (TIS). Data are the mean ± SEM (n = 4). *P < 0.05 and **P <0.01 in the indicated columns. Bar = 50 μm.
BW, body weight; DFAT, dedifferentiated fat; SEM, standard error of the mean.
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MCs.
Effects of implantation of DFAT cells with TSG-6 siRNA on
mAb 1-22-3-induced glomerulonephritis
We confirmed significant (P <0.05) suppression of TSG-
6 protein concentration in conditioned medium from
cultured DFAT cells transfected with 20 nM TSG-6
siRNA (Additional file 1: Figure S3A). In addition, serum
concentration of TSG-6 was significantly (P <0.05) lower
in mAb 1-22-3-injected rats implanted with DFAT cells
with TSG-6 siRNA compared to rats implanted with
DFAT cells with control siRNA (Additional file 1: Figure
S3B). Implantation of DFAT cells with control siRNA
through the tail vein reduced the increases in protein-
uria. Implantation of DFAT cells with TSG-6 siRNA
through the tail vein did not reduce proteinuria that was
significantly (P <0.05) higher than proteinuria in rats im-
planted with DFAT cells with control siRNA. Injection
of mAb 1-22-3 increased serum levels of BUN and cre-
atinine. Systematic implantation of DFAT cells with
TSG-6 siRNA through the tail vein did not decreasethe increased serum levels of BUN and creatinine
(Figure 12B, 12C).
Figure 13 shows effects of implantation of DFAT cells
with TSG-6 siRNA on GIS and TIS of mAb 1-22-3-
induced glomerulonephritis. Injection of mAb 1-22-3
significantly (P <0.01) increased the GIS and TIS. Implant-
ation of DFAT cells with control siRNA through tail vein
resulted in a significant (P <0.01) reduction in the in-
creased GIS and TIS. Whereas implantation of DFAT cells
with TSG-6 siRNA through tail vein did not affect the in-
creased GIS and TIS (Figure 13).
Discussion
As an animal model for renal diseases, anti Thy-1.1 anti-
body induces transient glomerulonephritis with spontan-
eous improvement [20], whereas mAb 1-22-3 induces
glomerulonephritis with significant proteinuria and pro-
gressive mesangial injury. In this study, one injection of
mAb 1-22-3 induced mesangiolysis and glomerular in-
flammatory cell infiltration in unilaterally nephrecto-
mized rats. In addition, expression of Kim-1, collagen IV
and fibronectin mRNAs was increased, and expression
Figure 8 Effects of implantation of DFAT cells on leukocyte accumulation in glomeruli in mAb 1-22-3-injected rats. Wistar rats were nephrectomized
and injected without mAb 1-22-3 (Control) or with 0.5 mg mAb 1-22-3 through the tail vein seven days after nephrectomy. Thirty-five days
after nephrectomy, saline (Saline) or 106 DFAT cells were injected through the renal artery (DFAT ia) or tail vein (DFAT iv). Sixty-three days after
nephrectomy, the left kidney was removed. Immunohistochemical analysis was performed. Numbers of ED1 cells (A: monocytes/macrophages),
OX1+ cells (B: common leukocytes), OX19+ cells (C: pan T cells) and OX38+ cells (D: CD4 T lymphocytes) per glomerular cross-section were counted in
50 randomly selected full-sized glomeruli. Data are the mean ± SEM (n = 6). *P <0.05 and **P <0.01 in the indicated columns. Bar = 50 μm. DFAT,
dedifferentiated fat; mAb, monoclonal antibody; SEM, standard error of the mean.
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Figure 9 Effects of implantation of DFAT cells on mRNA expression of cytokines in renal cortex of mAb 1-22-3-injected rats. Wistar rats were
nephrectomized and injected without mAb 1-22-3 (Control) or with 0.5 mg mAb 1-22-3 through the tail vein seven days after nephrectomy.
Thirty-five days after nephrectomy, saline (Saline) or 106 DFAT cells were injected through the renal artery (DFAT ia) or tail vein (DFAT iv). Sixty-three
days after nephrectomy, the left kidney was removed. Real-time quantitative PCR was performed for expression of IL-6 (A), IL-10 (B), IL-12β (C) and
TGF-β1 (D) mRNAs. Data are the mean ± SEM (n = 6). *P <0.05 and **P <0.01 in the indicated columns. DFAT, dedifferentiated fat; mAb, monoclonal
antibody; SEM, standard error of the mean; TGF- β1, transforming growth factor- β1.
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rats injected with mAb 1-22-3, indicating that mAb 1-
22-3 induced acute mesangial injury as well as podocyte
injury. These results suggest that mAb 1-22-3-induced
glomerulonephritis is an ideal animal model for progres-
sive immune-mediated nephropathy.
We examined the effects of implantation of DFAT cells
on mAb 1-22-3-induced glomerulonephritis in rats.
DFAT cells can be obtained from small amounts of adi-
pose tissue and express HLA-A, −B, and -C, but not
HLA-DR. Thus, DFAT cells may be an attractive cell
source for allogenic implantation. In response to specific
culture conditions, DFAT cells can differentiate into adi-
pocytes, osteoblasts, chondrocytes, myofibroblasts, skel-
etal myocytes, and cardiomyocytes [21-23]. Thus, DFAT
cells are considered to be a suitable cell source for re-
generative medicine for the mesenchymal organs. In the
present experiments, implantation of DFAT cells de-
creased proteinuria and improved glomerular injury as
well as interstitial degeneration of the kidney in mAb 1-
22-3-injected rats. Notably, the systematic implantation
of DFAT cells through the tail vein was more effective in
reducing proteinuria and renal degeneration than direct
implantation. Labeled DFAT cells implanted through thetail vein were trapped mainly in the lung and not deliv-
ered to the kidney. These findings indicate the possibility
that DFAT cells trapped in the lung release some anti-
inflammatory and/or immunosuppressive substances to
improve renal injury in mAb 1-22-3 injected rats.
We examined the effects of implantation of DFAT cells
on adriamycin-induced glomerulonephropathy. Adria-
mycin induces focal segmental glomerulosclerosis with
severe proteinuria with interstitial degeneration of the
kidney [24]. Adriamycin induces injury by direct toxic
damage to the glomerulus with subsequent tubulointer-
stitial injury with damages of the glomerular filtration
barrier including glomerular endothelial cells, glomeru-
lar basement membrane and podocytes [25]. Subse-
quently, adriamycin-induced nephropathy shows severe
tubulointerstitial inflammation with marked infiltration
by T and B lymphocytes and macrophages [26]. How-
ever, it has been reported that adriamycin can induce
structural and functional injury in immunodeficient mice
without infiltration by T and B lymphocytes. These re-
ports suggest adriamycin directly induces degeneration
of glomerulus with tubulointerstitial injury without im-
munological mechanisms, which accompanies subse-
quent immunological injury of kidney with infiltration of
Figure 10 Expression of TSG-6 in kidney from mAb 1-22-3-injected rats after implantation of DFAT cells and production of TSG-6 protein in cultured
DFAT cells stimulated with TNF-α. Wistar rats were nephrectomized and injected without mAb 1-22-3 (Control) or with 0.5 mg mAb 1-22-3 through
the tail vein seven days after nephrectomy. Thirty-five days after nephrectomy, saline (Saline) or 106 DFAT cells were injected through the renal artery
(DFAT ia) or through the tail vein (DFAT iv) in rats. Sixty-three days after nephrectomy, all rats were killed and the left kidney was removed. Real-time
quantitative PCR was performed for expression of TSG-6 (A) and TNF-α (B) mRNAs. C) Levels of TSG-6 in culture medium were determined using ELISA
kits. D) Concentrations of TSG-6 in conditioned medium from 106 fibroblast or from 106 DFAT cells in culture were determined by ELISA kit.
Serum levels of TSG-6 were determined in serum from Wistar rats injected with saline and 106 DFAT cells. Data are the mean ± SEM (n = 6).
*P <0.05 and **P <0.01 in the indicated columns. DFAT, dedifferentiated fat; mAb, monoclonal antibody; SEM, standard error of the mean;
TSG-6, TNF-stimulated gene-6.
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improve the adriamycin-induced glomerular degener-
ation and rather increased the proteinura. It is, therefore,
considered that the systematic implantation of DFAT
cells mainly improved the renal degeneration of mAb 1-
22-3-induced glomerulonephritis through immunosup-
pressive mechanisms.
It has recently been established that MSCs exert im-
munosuppressive effects through the inhibition of activated
T cells and natural killer cells. MSCs can inhibit immune
responses in non-human leukocytes in an antigen-
restricted manner [27,28]. Implantation of MSCs has
been reported to suppress systematic lupus erythema-
tosus [29] and inflammatory bowel diseases [30]. The
complex mechanisms underlying the immunosuppres-
sive effects of MSCs are reported to be the increases in
regulatory T cells through the induction of prostaglan-
din E2 (PGE2), indoleamine 2,3-dioxygenase [31], and
the release of several cytokines [32] and hepatocytegrowth factor (HGF) [33]. HGF has been reported to
have immunosuppressive effects on reactions caused
by transplantation and autoimmune diseases [34]. In
the present experiments, the immunostaining of HGF
was not different in renal cortex from control rats,
mAb 1-22-3-injected rats injected with saline or DFAT
cell-implanted rats, indicating that HGF was not involved
in the improvement of renal degeneration in mAb 1-22-3
injected rats as a result of DFAT cell implantation
(Additional file 1: Figure S1).
We examined the effects of DFAT cell implantation on
leukocyte influx into the kidney in mAb 1-22-3-injected
rats. Infiltration of ED1+ pan monocytes/macrophages,
OX1+ common leukocytes and OX19+ pan T cells was
increased in the glomeruli in kidney from mAb 1-22-3-
injected rats. DFAT cell implantation significantly de-
creased ED1+, OX1+ and OX19+ cells, whereas OX38+
helper T cells were significantly increased. These find-
ings indicate the suppression of macrophage infiltration
Figure 11 Production of TSG-6 from mesangial cells (MCs) by transwell coculture of DFAT cells. MCs from stroke-prone spontaneously hypertensive
rats (SHR-SP) were plated at 4,000 cells per cm2 in the bottom well of a six-well transwell coculture system. DFAT cells from Wistar rats were separately
plated at 1,000 cells per cm2 on the upper inserts of a transwell coculture system and cultured for seven days. A) Transwell coculture systems of DFAT
cells and MCs. MC: MCs alone. DFAT: DFAT cells alone. MC+ DFAT: MCs were seeded in the lower chamber and DFAT cells were seeded in the upper
chamber. B) Levels of TSG-6 in culture medium were determined using ELISA. C) Expression of TSG-6 mRNA was determined by real-time RT-PCR in
MCs from SHR-SP or DFAT cells. Data are the mean ± SEM (n = 6). *P <0.05 and **P <0.01 in the indicated columns. DFAT, dedifferentiated fat; SEM,
standard error of the mean; TSG-6, TNF-stimulated gene-6.
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1-22-3-induced glomerulonephritis might be mechanisms
underlying the systematic implantation-induced immuno-
suppression. Furthermore, expressions of IL-6, IL-10 and
IL-12β mRNAs, which were suppressed by the implant-
ation of DFAT cells, were increased in renal cortex fromFigure 12 Effects of implantation of DFAT cells with TSG-6 siRNA on prote
Wistar rats were injected with 0.5 mg of mAb 1-22-3 and saline or 106 D
through the tail vein. Twenty-one days after the neflectomy urine was col
(A), and serum levels of BUN (B) and creatinine (Cre) (C) were measured. D
Bar = 50 μm. BUN, blood urea nitrogen; DFAT, dedifferentiated fat; mAb, m
TNF-stimulated gene-6.mAb-1-22-3-injected rats. IL-6, IL-10 and IL-12β have
been reported to be mainly produced from macrophages
[35], indicating that the implantation of DFAT cells
ameliorated the immunological glomerulonephritis by
suppression of macrophage infiltration into the kidney
with inhibition of IL-6, IL-10 and IL-12β. However,inuria and renal function in mAb 1-22-3-induced glomerulonephritis.
FAT cells transfected with 20 nM TSG-6 siRNA or 20 nM control siRNA
lected for 24 hours and blood was sampled. Urinary protein excretion
ata are the mean ± SEM (n = 4). *P <0.05 in the indicated columns.
onoclonal antibody; SEM, standard error of the mean; TSG-6,
Figure 13 Effects of implantation of DFAT cells with TSG-6 siRNA on degeneration of renal cortex in mAb 1-22-3-induced glomerulonephritis.
Wistar rats were injected with 0.5 mg of mAb 1-22-3 and saline or 106 DFAT cells transfected with 20 nM TSG-6 siRNA or 20 nM control siRNA
through the tail vein. Fourteen days after the injections, all rats were killed and the left kidney was removed. A) The paraffin sections of removed
renal cortex were stained with hematoxylin and eosin (H & E). Renal cortical thickness was measured under high magnification (x400). B) Glomerular
injury score (GIS). C) Tubulointerstitial injury score (TIS). Data are the mean ± SEM (n = 4). **P <0.01 in the indicated columns. Bar = 50 μm. DFAT,
dedifferentiated fat; mAb, monoclonal antibody; SEM, standard error of the mean; TSG-6, TNF-stimulated gene-6.
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3-induced glomerulonephritis, when DFAT cells were
trapped in the lung, remain to be elucidated.
It has been demonstrated that intravenously infused
MSCs were mostly trapped as emboli in the lung and
that they secrete an anti-inflammatory protein, TSG-6,
which decreases inflammatory responses and improves
injured organs [36]. TSG-6, a 30 kDa protein, is induced
by a number of signaling molecules, principally TNF-α
and IL-1 and may be induced by mechanical stimuli in
mesenchymal cells. It is found to be correlated with pro-
teoglycan synthesis and aggregation [37]. Wang et al.
[38] recently demonstrated that MSCs trapped in the
lung produce TSG-6 after intravenous injection, which
induced anti-inflammatory and immunosuppressive ef-
fects. Interestingly, they also demonstrated that intraven-
ous injection of conditioned medium of cultured MSCs
increased serum levels of TSG-6 as well as tissue levels
of TSG-6 in injured peritoneum [39]. In the presentexperiments, the systematic implantation of DFAT cells
increased serum levels of TSG-6 as well as the expres-
sion of TSG-6 in the kidney of mAb 1-22-3-injected rats.
In addition, the systematic implantation increased ex-
pression of TNF-α mRNA in renal cortex from mAb 1-
22-3-injected rats, which may stimulate the expression
of TSG-6 in renal cortex. Moreover, we found that pro-
duction of TSG-6 protein was higher in DFAT cells than
in fibroblasts and that the implantation of DFAT cells in-
creased serum levels of TSG-6 protein in rats. These
findings suggest that the implanted DFAT cells abun-
dantly produced TSG-6, which ameliorated the mAb
1-22-3-induced glomerulonephritis.
To investigate whether separately placed DFAT cells
can increase TSG-6 in MCs, we employed a transwell
coculture system. Production of TSG-6 in conditioned
medium from MCs with DFAT cells was higher than
MCs or DFAT cells alone. Expression of TSG-6 mRNA
in MCs cocultured with DFAT cells was higher than in
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placed DFAT cells increased TSG-6 in MCs. Recently,
Roddy et al. [40] demonstrated that MSCs are activated
by proinflammatory signals to introduce two phases: 1)
the activated MSCs secrete PGE2, which drives resident
macrophages of type 1 proinflammatory phenotype to-
ward type 2 anti-inflammatory phenotype macrophages;
and 2) the activated MSCs secrete TSG-6, which inter-
acts with CD44 on resident macrophages to decrease
toll-like receptor 2. TSG-6 from MSCs inhibits the initial
activation of resident macrophages by modulating toll-
like receptor 2/CD44/NF-kB signaling and thereby de-
creases the phase II inflammatory response. These
findings are identical to our own in that the systematic
implantation of DFAT cells reduced macrophage infiltra-
tion into the kidney with decreases the expression of IL-6,
IL-10 and IL-12β mRNAs in mAb 1-22-3-injected rats.
In order to explore the contribution of TSG-6 in the
amelioration of the mAb 1-22-3-induced glomerulo-
nephritis with implantation of DFAT cells, we examined
effects of implantation of DFAT cells transfected with
TSG-6 siRNA. Implantation of DFAT cells with control
siRNA through the tail vein reduced the increases in
proteinuria. Systematic implantation of DFAT cells with
TSG-6 siRNA through the tail vein did not reduce pro-
teinuria, increases in serum BUN and creatinine and
renal degeneration in the mAb 1-22-3-injected rats.
These results suggest that the DFAT cells trapped in the
lung produced TSG-6 in serum as well as in the kidney,
which improved the renal degeneration and the renal
dysfunction in rats with the mAb 1-22-3.
Conclusions
Systematic implantation of DFAT cells effectively amelio-
rated mAb 1-22-3-induced glomerulonephritis through
immunosuppressive effects accompanied by the suppres-
sion of macrophage infiltration and expression of IL-6,
IL-10 and IL-12β, and increased production of serum
and renal TSG-6 that improved the mAb 1-22-3-induced
renal degeneration by the immunosuppressive effects of
TSG-6. Thus DFAT cells will be a suitable cell source for
the treatment of immunological progressive renal diseases.
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and in serum with TSG-6 siRNA.
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